OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

Executive Summary

• OneMedNet entered into a collaboration with Inka Health (a subsidiary of Onco‑Innovations Limited) granting access to its iRWD™ platform powered by Palantir Foundry.
• The partnership will support development of Onco‑Innovations’ PNKP Inhibitor Technology targeting PTEN/SHP1‑deficient cancers, including patient responder identification and indication expansion.
• Both companies highlight the ability to rapidly identify rare molecularly defined patient populations, de‑risk clinical programs, and improve capital efficiency.

Key Details

• Parties: OneMedNet Corporation; Inka Health (wholly‑owned subsidiary of Onco‑Innovations Limited).
• Platform Access: Inka Health receives access to OneMedNet’s iRWD™ platform via a selective pilot program after technical evaluation and qualification.
• Purpose: Accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco‑Innovations’ proprietary PNKP Inhibitor Technology.
• Focus Areas:
• Patient responder identification for PTEN/SHP1‑deficient tumors.
• Indication expansion beyond advanced metastatic colorectal cancer.
• Complementary real‑world evidence to inform clinical and regulatory decisions.
• Additional Use: Inka Health will leverage the platform to further develop its SynoGraph™ AI model, which predicts success and safety of new cancer treatments using multimodal medical data.
• Technology Stack: iRWD™ platform is powered by Palantir (PLTR) Foundry, providing regulatory‑grade real‑world oncology data with AI‑augmented search capabilities.
• Strategic Fit: Collaboration aligns with the original architectural intent of iRWD™ to enable rapid identification and characterization of rare, molecularly defined patient cohorts at scale.

Notable Quotes

“This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high‑value patient populations to accelerate innovation,” – Aaron Green, CEO & President, OneMedNet.

“Access to high‑quality U.S. oncology real‑world data is a critical enabler for PNKP Inhibitor Technology… helping us de‑risk development while improving capital efficiency for shareholders,” – Thomas O’Shaunghnessy, CEO, Onco‑Innovations.